Cargando…
Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492540/ https://www.ncbi.nlm.nih.gov/pubmed/37691972 http://dx.doi.org/10.2147/JHC.S423684 |
_version_ | 1785104277910323200 |
---|---|
author | Yang, Hui Yang, Tiequan Qiu, Guangpin Liu, Jie |
author_facet | Yang, Hui Yang, Tiequan Qiu, Guangpin Liu, Jie |
author_sort | Yang, Hui |
collection | PubMed |
description | PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with TACE-L, and analyzed factors affecting prognosis. MATERIALS AND METHODS: A total of 122 patients were treated with either TACE-L-P (n = 64) or TACE-L (n = 58), and their data was collected and analyzed. We assessed tumor response, progression-free survival (PFS), prognostic factors for PFS and adverse events (AEs) to compare the efficacy and safety of TACE-L-P with TACE-L for patients with uHCC. RESULTS: TACE-L-P group’s patients had a better objective response rate (ORR) (57.8% vs 41.4%, P = 0.047) and a better disease control rate (93.7% vs 81%, P = 0.013), as long as a longer median progression-free survival (PFS) (8 months vs 4.6 months, HR: 0.461; 95% CI: [0.314–0.675]; P = 0.001) than TACE-L group’s patients. According to multivariate analysis, independent prognostic factors for PFS included treatment option (TACE-L-P / TACE-L; RH = 0.461; 95% CI [0.314–0.675]; P = 0.001), PVTT (Yes/No; RH =1 0.599;95% CI [1 0.095–2 0.336]; P=0 0.017), extrahepatic metastasis (Yes/No; RH=1 0.847;95% CI [1 0.176 −2 0.909]; P=0 0.008). AEs in TACE-L-P group was similar with TACE-L group. CONCLUSION: TACE-L-P has more promising clinical outcomes in patients with uHCC than TACE-L, and their safety is similar. |
format | Online Article Text |
id | pubmed-10492540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104925402023-09-10 Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study Yang, Hui Yang, Tiequan Qiu, Guangpin Liu, Jie J Hepatocell Carcinoma Original Research PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with TACE-L, and analyzed factors affecting prognosis. MATERIALS AND METHODS: A total of 122 patients were treated with either TACE-L-P (n = 64) or TACE-L (n = 58), and their data was collected and analyzed. We assessed tumor response, progression-free survival (PFS), prognostic factors for PFS and adverse events (AEs) to compare the efficacy and safety of TACE-L-P with TACE-L for patients with uHCC. RESULTS: TACE-L-P group’s patients had a better objective response rate (ORR) (57.8% vs 41.4%, P = 0.047) and a better disease control rate (93.7% vs 81%, P = 0.013), as long as a longer median progression-free survival (PFS) (8 months vs 4.6 months, HR: 0.461; 95% CI: [0.314–0.675]; P = 0.001) than TACE-L group’s patients. According to multivariate analysis, independent prognostic factors for PFS included treatment option (TACE-L-P / TACE-L; RH = 0.461; 95% CI [0.314–0.675]; P = 0.001), PVTT (Yes/No; RH =1 0.599;95% CI [1 0.095–2 0.336]; P=0 0.017), extrahepatic metastasis (Yes/No; RH=1 0.847;95% CI [1 0.176 −2 0.909]; P=0 0.008). AEs in TACE-L-P group was similar with TACE-L group. CONCLUSION: TACE-L-P has more promising clinical outcomes in patients with uHCC than TACE-L, and their safety is similar. Dove 2023-09-05 /pmc/articles/PMC10492540/ /pubmed/37691972 http://dx.doi.org/10.2147/JHC.S423684 Text en © 2023 Yang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yang, Hui Yang, Tiequan Qiu, Guangpin Liu, Jie Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study |
title | Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study |
title_full | Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study |
title_fullStr | Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study |
title_full_unstemmed | Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study |
title_short | Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study |
title_sort | efficacy and safety of tace combined with lenvatinib and pd-(l)1 inhibitor in the treatment of unresectable hepatocellular carcinoma: a retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492540/ https://www.ncbi.nlm.nih.gov/pubmed/37691972 http://dx.doi.org/10.2147/JHC.S423684 |
work_keys_str_mv | AT yanghui efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy AT yangtiequan efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy AT qiuguangpin efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy AT liujie efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy |